Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CiplaLUX:CIPLA 96 3-Year EPS without NRI Growth Rate is 11.50% as of Jun. 2026, which is 8% below its 10-year median of 12.50. GuruFocus rates LUX:CIPLA with a GF Score™ of 96/100 and a GF Value™ of $20.60. The stock has 3 warning signs investors should review. Among 783 Drug Manufacturers companies, Cipla ranks better than 54.15% on this metric.
During the past 12 months, Cipla's average EPS without NRI Growth Rate was -33.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 11.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 15.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Cipla was 29.70% per year. The lowest was -4.00% per year. And the median was 12.50% per year.
Cipla (LUX:CIPLA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Cipla 3-Year EPS without NRI Growth Rate Related Terms
LUX:CIPLA vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Cipla's 3-Year EPS without NRI Growth Rate falls into.
Cipla 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 11.50% mean?
Cipla (LUX:CIPLA) has a 3-Year EPS without NRI Growth Rate of 11.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cipla and its competitors. This is near median its historical median of 12.50. According to the industry distribution chart, Cipla ranks #359 out of 783 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is Cipla's 3-Year EPS without NRI Growth Rate too high?
Cipla's current 3-Year EPS without NRI Growth Rate of 11.50% is near median its 10-year median of 12.50. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Cipla's value of 11.50% is 17.3% above this industry median. Based on the distribution chart, Cipla ranks #359 out of 783 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cipla has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #359 out of 783 companies for 3-Year EPS without NRI Growth Rate. This puts Cipla in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Cipla's value of 11.50% is 17.3% above this benchmark. While the company's 10-year median is 12.50 vs. the industry median of 9.80, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current 3-Year EPS without NRI Growth Rate of 11.50% is 17.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cipla and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current 3-Year EPS without NRI Growth Rate is 11.50%, which is near median its own 10-year median of 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current 3-Year EPS without NRI Growth Rate of 11.50%. The stock's GF Value™ is $20.60, compared to a current price of $18.10 — trading 12.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 11.50%, which is near median its 10-year median of 12.50 and 17.3% above the Drug Manufacturers industry median of 9.80. Cipla's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current 3-Year EPS without NRI Growth Rate is 11.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 12.1% below its estimated GF Value™ of $20.60.
Key valuation signals for LUX:CIPLA:
3-Year EPS without NRI Growth Rate: 11.50% (near median its 10-year median of 12.50)
GF Value™: $20.60 vs. price of $18.10 (12.1% below fair value)
Industry Position: 17.3% above the Drug Manufacturers median (#359 of 783)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
96GF Score
Get the complete analysis for LUX:CIPLA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
